E. TABOR, M.D.; R.J. GERETY, M.D.; P.G. FOUTCH, D.O.; W.D. CAREY, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: In a recent letter Leibowitz and Vladutiu (1) question whether increased sensitivity of radioimmunoassays for antibody to the hepatitis B surface antigen (anti-HBs) has resulted in the detection of low titers of cross-reacting antibodies that are not specific for the hepatitis B surface antigen (HBsAg). This possibility has led some authors to recommend that low anti-HBs titers (low radioimmunoassay ratios) not be considered indicative of a protective level of anti-HBs, when deciding who should receive the hepatitis B vaccine among persons at high risk for hepatitis B infection (2).
In contrast, the anti-HBs detected in the serum
TABOR E, GERETY R, FOUTCH P, et al. Specificity of Tests for Antibody to Hepatitis B Surface Antigen in Patients with Concomitant Antibody and Antigen. Ann Intern Med. 1984;101:277. doi: 10.7326/0003-4819-101-2-277_1
Download citation file:
Published: Ann Intern Med. 1984;101(2):277.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use